Rexgenero receives confirmation from EMA / CAT that REX-001 meets the definition of an ATMP


London UK. Rexgenero receives notification from The Committee for Advanced Therapies (CAT) of the European Medicines Agency (EMA) that EMA / CAT considers REX-001 to be a tissue engineered product on the basis that cells are not intended to be used for the same essential function and restore physiological functions (regenerating, repairing and replacing human tissue) by exerting pharmacological, immunological and metabolic actions and therefore is an Advanced Therapy Medicinal Product (ATMP) as provided in Article 2(1) of Regulation (EC) No 1394/2007.

innovative cell therapies
Contact us